Emris Pharma · raw details

EMRIS Pharma is developing a novel small molecule topically administrated for the prevention of skin toxicities induced by EGFR inhibitors (EGFRi). This innovative therapy intends to improve cancer patients’ quality of life and compliance with cancer therapy.

Current treatment strategies and new developments focus on symptom reduction post-EGFR inhibition when our solution blocks the initial trigger causing skin toxicity, the drug-receptor interaction. The company new approach will prevent skin toxicity, enabling more cancer patients to go about their daily lives without compromising their anticancer treatment.

Its solution (SDT 011) is targeting a huge market with global unmet need. The market is also expected to substantially grow due to new combinations of cancer treatments with EGFRi and a potential product approval of new EGFRi bi-specific antibodies.

SDT 011 (EMR-001) is the first-to-market product in the pipeline of the company. Additional new candidate compounds are currently in development for Tyrosine Kinase Inhibitors’ induced skin toxicities that can substantially contribute to the market size.